ClinicalTrials.gg
RecruitingNCT07614594Updated Jul 2, 2026

Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis

An observational study in Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma and UTUC, sponsored by Henan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Henan Provincial People's Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 90 studies in Carcinoma, Transitional Cell with a site in China — 53 open to participants now, 58 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
6th of 19
800 · median 400
Started
2019
with 7 others
Observational
19 of 90
12 open now
Primary completion
2030-12
later than 57 of 57 live
Registered
80th of 90
by date

Among the 90 studies in Carcinoma, Transitional Cell with a site in China, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 8 that started in 2019, is one of 19 observational ones, reaches primary completion later than 57 of the 57 other live ones, and was the 80th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

53 of the 90 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC). The study enrolls adult patients presenting with gross or microscopic hematuria and imaging evidence of a space-occupying lesion in the renal pelvis, ureter, or bladder, who are scheduled for diagnostic cystoscopy and/or surgical tissue sampling. Histopathological examination serves as the reference standard.

Stage 1 (Completed, 8th October 2019 - 31st December 2023):

A total of 113 participants have been enrolled. Owing to sufficient research funding, all participants in this stage underwent four urine-based tests: cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17-gene mutation panel.

Stage 2 (Ongoing, from 1st January 2024):

The testing protocol was refined to focus on urine DNA methylation alone, owing to limited research funding and the lower cost of DNA methylation compared with the 17-gene mutation panel. As of registration (May 2026), approximately 330 participants have been enrolled.

All enrolled participants are categorized into two groups based on histopathology: a UC group (including upper tract urothelial carcinoma [UTUC] and bladder cancer [BC]) and a non-UC control group. The primary outcome is the diagnostic accuracy (area under the receiver operating characteristic curve [AUC] with 95% confidence interval, sensitivity, and specificity) of the four urine-based tests in the Stage 1 cohort. The key secondary outcome is the diagnostic accuracy of urine DNA methylation in the Stage 2 cohort. Other secondary outcomes include paired comparisons of AUCs among the four tests in the Stage 1 cohort. Exploratory analyses will include the diagnostic performance of urine cytology in a subset of Stage 2 participants with UTUC, as well as subgroup analyses by tumor site (UTUC vs. BC).

Because this study is purely observational and non-interventional, prospective registration was not a regulatory or institutional requirement when enrollment began in 2019. This record is being submitted prior to any data analysis to ensure consistency with current research transparency standards.

03

Conditions studied

  • Urothelial Carcinoma (UC)
  • Upper Tract Urothelial Carcinoma
  • UTUC
  • Bladder Cancer (BC)

Keywords

  • urothelial carcinoma
  • upper tract urothelial carcinoma
  • DNA methylation
  • 17 genes mutation
  • diagnosis
  • bladder cancer
  • diagnostic efficacy
  • urine sample
  • cytology
  • fluorescence in situ hybridization
  • non-invasive detection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (≥18 years) presenting with gross or microscopic hematuria, who present with space-occupying lesions in the renal pelvis, ureter, or bladder by imaging (B-ultrasonography, CT, or MRI) and are scheduled for a diagnostic procedure to obtain tissue histopathological diagnosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible if they meet all of the following criteria:

  1. Age ≥ 18 years.
  2. Presence of gross or microscopic hematuria.
  3. Imaging (B-ultrasonography, CT, or MRI) showing a renal pelvic, ureteral, or bladder lesion.
  4. Scheduled for surgery for tissue histopathological diagnosis.
  5. Able to provide written .

Exclusion criteria

Exclusion Criteria

  1. Inadequate urine sample (poor quality or insufficient volume).
  2. Lack of final histopathological diagnosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Urothelial Carcinoma Group

    Patients with space-occupying lesions diagnosed with UC by histopathology.

  • Non-Urothelial Carcinoma Group

    Non-Urothelial Carcinoma Group. Description: Patients with space-occupying lesions not diagnosed with UC.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of four urine-based tests in the Stage 1 cohort

    Area under the receiver operating characteristic curve (AUC) with 95% confidence interval (CI), sensitivity, and specificity of cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17-gene mutation panel for the detection of urothelial carcinoma (UC) in the Stage 1 cohort, using histopathology as the reference standard.

    Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection)

Secondary outcomes

  1. Diagnostic accuracy of urine DNA methylation in the Stage 2 cohort

    AUC with 95% CI, sensitivity, and specificity of urine DNA methylation for the detection of UC in all participants enrolled in Stage 2, using histopathology as the reference standard.

    Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection).

  2. Paired comparisons of AUCs among the four tests in the Stage 1 cohort

    Paired comparisons of areas under the ROC curves (AUCs) among cytology, FISH, DNA methylation, and the 17-gene mutation panel for detecting UC in the Stage 1 cohort.

    Time frame: At the time of urine collection and subsequent histopathological diagnosis (within 4 weeks of urine collection).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2030, 134 months after the start.

Of 61 observational studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 89. This study's planned 134 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 29, 2026
StartActual
Oct 8, 2019
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614594
Lead sponsor
Henan Provincial People's Hospital
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Oct 8, 2019
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 2, 2026

Study contacts

Kunpeng Shu
Contact
kunpengshu@163.com
+8615515696659
Junya Yan, PhD
Contact
yjunya1471@126.com
+8618811510659
Zhifeng Wang, PhD
principal investigator · Henan Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion